Contribution of an antiviral drug (Valaciclovir) in the treatment of generalized periodontitis (stage III or IV and grade A, B or C)
- Conditions
- Generalized periodontitis (stage III or IV and grade A, B or C)Therapeutic area: Diseases [C] - Virus Diseases [C02]Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2022-501957-35-00
- Lead Sponsor
- Centre Hospitalier Universitaire De Nice
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 142
Age = 18 years, Diagnosis of periodontitis induced by bacterial biofilms of dental plaque, generalized, stage III or IV and grade A, B or C, Patients of childbearing age will need to use an effective method of contraception for the duration of their study participation, Signature of informed consent, Membership of a social security scheme
Necrotizing periodontitis, Renal failure (creatinine clearance < 60 ml/min), Systemic antibiotic therapy or any medication affecting the periodontal environment (systemic antibiotics, antiepileptics, immunosuppressants, calcium inhibitors) taken within 3 months of inclusion, Nephrotoxic medications (aminoglycosides, organoplatines, iodized contrast agents, methotrexate, pentamidine, foscarnet, ciclosporine and tacrolimus), Hypersensitivity to valaciclovir, aciclovir or one of the excipients, History of DRESS syndrome under valaciclovir treatment, Pathologies requiring prophylactic antibiotic therapy (which may influence treatment), Non-surgical periodontal treatment completed within 6 months prior to inclusion, Patients with enhanced protection, namely lactating women, persons deprived of liberty by judicial or administrative decision, persons over 18 under legal protection, Patients who do not accept conventional therapy (gingival debridement not covered by the social security system) performed in each centre, Periodontitis as a direct manifestation of systemic diseases, Major systemic pathologies (diabetes, HIV, cancers, immunocompromised patients), Negative serology for EBV: a blood test will be performed. The results will be communicated to the patient by the dental surgeon, Pregnant women: a blood pregnancy test will be carried out for women of reproductive age who do not have contraception. Results will be communicated to the patient by the dental surgeon
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method